Alere Inc., a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration has granted CLIA waiver for the Alere i Strep A test. The test, which was cleared for marketing by the FDA in April 2015, is the first molecular platform that detects Group A Streptococcus (GAS) bacteria in 8 minutes or less.
↧